Drugs / ChAdOx1 MERS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04170829 | Dec 2019 → Nov 2020 | Middle East respiratory syndrome | King Abdullah International Medical Research Center | Completed | No outcome recorded |
| Phase 1 | NCT03399578 | Mar 2018 → Sep 2021 | Middle East respiratory syndrome | University of Oxford | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1 MERS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04170829 ↗ |
| Modality | Vaccine | “candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS” PMID 32325038 ↗ Apr 2020 |
| Route | Intramuscular | “All vaccinations will be administered intramuscularly.” NCT03399578 ↗ |